{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:10:22Z","timestamp":1760094622775,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["41004"],"award-info":[{"award-number":["41004"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.biopha.2011.10.004","type":"journal-article","created":{"date-parts":[[2011,12,31]],"date-time":"2011-12-31T00:16:37Z","timestamp":1325290597000},"page":"173-174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone"],"prefix":"10.1016","volume":"66","author":[{"given":"Natasa","family":"Colovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Suvajdzic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada","family":"Kraguljac Kurtovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Dencic Fekete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Drulovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Vidovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragica","family":"Tomin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2011.10.004_bib0005","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1590\/S0004-282X2005000200024","article-title":"Acute myeloid leukaemia induced by mitoxantrone","volume":"63","author":"Arruda","year":"2005","journal-title":"Arq Neuropsiquiatr"},{"key":"10.1016\/j.biopha.2011.10.004_bib0010","doi-asserted-by":"crossref","first-page":"41","DOI":"10.7224\/1537-2073-10.2.41","article-title":"Mitoxantrone-associated leukemia in multiple sclerosis-case studies","volume":"10","author":"Woo","year":"2008","journal-title":"Int J MS Care"},{"key":"10.1016\/j.biopha.2011.10.004_bib0015","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic instrument in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2011.10.004_bib0020","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood-2003-07-2462","article-title":"Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group","volume":"103","author":"Sanz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2011.10.004_bib0025","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1191\/1352458503ms898xx","article-title":"Therapy-related leukemia in mitoxantrone patients (letter)","volume":"9","author":"Goodkin","year":"2003","journal-title":"Mult Scler"},{"key":"10.1016\/j.biopha.2011.10.004_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1191\/1352458502ms836oa","article-title":"A study of therapy-related acute leukemia after mitoxantrone therapy for multiple sclerosis","volume":"8","author":"Ghalie","year":"2002","journal-title":"Mult Scler"},{"key":"10.1016\/j.biopha.2011.10.004_bib0035","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1177\/1352458509107015","article-title":"Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required","volume":"8","author":"Pascual","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.biopha.2011.10.004_bib0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1352458508100967","article-title":"Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?","volume":"15","author":"Ellis","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.biopha.2011.10.004_bib0045","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3324\/haematol.2010.036657","article-title":"Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis","volume":"96","author":"Ammatuna","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2011.10.004_bib0050","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.0b013e318211c3c8","article-title":"Risk of acute promyelocytic leukemia in multiple sclerosis. Coding variants of DNA repair genes","volume":"76","author":"Hasan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2011.10.004_bib0055","first-page":"1410","article-title":"The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American academy of neurology","volume":"74","author":"Mariott","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.biopha.2011.10.004_bib0060","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1309\/C3G2-CXA0-HE9J-TKDR","article-title":"Therapy-related acute myeloid leukemia\/myelodysplasia with balanced 21q22 translocations","volume":"117","author":"Arber","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.biopha.2011.10.004_bib0070","first-page":"5673","article-title":"Sequence of cDNA comprising the human pur gene and sequence-specific single-stranded-DNA-binding properties of the encoded protein","volume":"12","author":"Bergemann","year":"1992","journal-title":"Mol Cell Biol"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332211001739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332211001739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:49:33Z","timestamp":1760093373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332211001739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0753332211001739"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2011.10.004","relation":{},"ISSN":["0753-3322"],"issn-type":[{"type":"print","value":"0753-3322"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2011.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}